Quotient

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

JERSEY, Channel Islands, May  11, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). Quotient has entered into an exclusive contract with hVIVO, whereby Quotient is hVIVO's exclusive supplier of COVID-19 antibody testing equipment, to support COVID-19 antibody testing in the UK.

Quotient Limited and hVIVO Announce Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UK

JERSEY, Channel Islands, May  01, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In Vitro Diagnostics Directive (IVDD 98/79/EC) and has CE marked (Conformité Européene) its SARS-CoV-2 (COVID-19) antibody microarray. The test is now available for sale in Europe and Switzerland.

Quotient Limited Announces CE Mark for its SARS-CoV-2 (COVID-19)  Antibody Microarray

JERSEY, Channel Islands, April  27, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test. The Company expects to complete the CE marking process and the submission of the FDA emergency use authorization for the MosaiQ COVID-19 Antibody Microarray in the next few days. Discussions with potential customers in Europe and the US are ongoing.

Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Final Performance Data

JERSEY, Channel Islands, April  21, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ COVID-19 Antibody Microarray as a research-use-only (RUO) product in Europe and the US. 

Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test  Performance Update

Quotient (NASDAQ: QTNT) shares are trading higher on Monday, after the company announced the completion of its coronavirus antibodies test development.

Why Quotient's Stock Is Moving Higher Today

JERSEY, Channel Islands, April  06, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the fully automated high throughput MosaiQ system in response to the global COVID-19 pandemic. One MosaiQ instrument can process up to 3000 antibody tests per day.

Quotient Limited Announces the Completion of the SARS-CoV-2  Antibody Test Development

JERSEY, Channel Islands, Feb.  24, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ multimodality multiplex Extended Serological Disease Screening (SDS) Microarray confirming feasibility of the MosaiQ system to address the needs of the Company’s donor center customers for serological disease screening.

Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study

JERSEY, Channel Islands, Feb.  14, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray.

Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray

Quotient has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Quotient Enters Oversold Territory

Quotient Ltd (QTNT) CEO Franz Walt on Q3 2020 Results - Earnings Call Transcript

JERSEY, Channel Islands, Jan.  10, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the commencement of the EU field trial activities for the extended Immunohematology (IH) microarray. In addition, the Company announced that the US Food and Drug Administration (FDA) has received its 510(k) submission for the initial SDS microarray and the MosaiQ™ system.

Quotient Limited Provides an Update on Recent Milestone Achievements for its MosaiQ Multimodality Multiplexing Diagnostic Platform

JERSEY, Channel Islands, Jan.  07, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial Officer (CFO) replacing Chris Lindop, the current CFO who plans to retire in May 2020. Mr. Buhler will assume the responsibilities of CFO on February 05, 2020 at which time Mr. Lindop will transition to an Executive Vice President role, reporting directly to Franz Walt, Quotient’s Chief Executive Officer (CEO). The Company also announced the appointment of Ed Farrell as Chief Operating Officer (COO). 

Quotient Announces Appointment of New Chief Financial Officer Peter Buhler and Chief Operating Officer Ed Farrell

JERSEY, Channel Islands, Dec.  05, 2019  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening (MDS) Microarray confirming feasibility of the MosaiQ system to address the needs of the Company’s donor center customers for molecular testing. Quotient is now moving forward in developing the MDS microarray as planned.

Quotient Limited Reports Concordance Data from MDS Concept Study

JERSEY, Channel Islands, Nov.  06, 2019  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per share. The net proceeds to the Company from this offering are expected to be approximately $78.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.  All of the ordinary shares sold in the offering were offered by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 of its ordinary shares. The offering is expected to close on November 12, 2019, subject to customary closing conditions.

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

Quotient Ltd (QTNT) CEO Franz Walt on Q2 2020 Results - Earnings Call Transcript

JERSEY, Channel Islands, Oct.  17, 2019  (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the positive Verification & Validation (V&V) data for the Extended Immunohematology (IH) Microarray.

Quotient Announces Positive Verification and Validation Results for Extended Immunohematology Microarray and Updates on Hypercare Sites and Revenue Performance in the Quarter

QTNT has an existing revenue stream from approved reagents.

Quotient Limited And Its MosaiQ Platform

Quotient Limited (QTNT) CEO Franz Walt on Q1 2020 Results - Earnings Call Transcript

Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Quotient Limited (QTNT) CEO Franz Walt on Q4 2019 Results - Earnings Call Transcript

News for Quotient Stock (QTNT)